It is clear that most of the published data on this topic were obtained in preclinical studies; our clinical study is the first to have shown a link between commonly prescribed OAT1/OAT3 inhibitors and the plasma pCS concentration in CKD patients. The gene discussed is SLC22A6; the disease is chronic kidney disease.